CTC Bio

CTC Bio Current Liabilities

The Current Liabilities of CTC Bio (060590.KQ) as of Oct 29, 2026 is 5.28 B KRW. In the previous year, Current Liabilities was 59.72 B KRW — a change of -91.15% (lower).

Current Liabilities

5.28 BKRW

YoY

-91.15%

Last updated:

Current Liabilities of CTC Bio is 2025 5.28 B KRW. Current Liabilities of CTC Bio was 2024 59.72 B KRW. It decreases by -91.15% lower compared to the previous year.

The CTC Bio Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
65.72 B KRW
Jan 1, 2019
97.26 B KRW
Jan 1, 2020
67.00 B KRW
Jan 1, 2021
62.18 B KRW
Jan 1, 2022
74.66 B KRW
Jan 1, 2023
59.32 B KRW
Jan 1, 2024
59.72 B KRW
Jan 1, 2025
5.28 B KRW
The CTC Bio Current Liabilities history
YEARCurrent LiabilitiesYoY
5.28 BKRW-91.15%
59.72 BKRW+0.68%
59.32 BKRW-20.55%
74.66 BKRW+20.06%
62.18 BKRW-7.19%
67.00 BKRW-31.11%
97.26 BKRW+47.99%
65.72 BKRW-6.81%
70.52 BKRW-10.44%
78.74 BKRW+13.36%
69.46 BKRW+228.58%
21.14 BKRW+62.04%
13.05 BKRW-5.13%
13.75 BKRW-31.90%
20.19 BKRW-46.32%
37.62 BKRW-3.24%
38.88 BKRW+133.55%
16.65 BKRW+75.20%
9.50 BKRW+83.24%
5.19 BKRW-39.53%
8.57 BKRW+53.82%
5.57 BKRW-30.09%
7.97 BKRW+214.39%
2.54 BKRW-6.07%
2.70 BKRW-3.95%
2.81 BKRW-6.67%
3.01 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CTC Bio Stock analysis

What does CTC Bio do? CTC Bio, Inc. generates revenue through the manufacture and sale of pharmaceuticals, including anticancer agents, antibiotics, bone injury treatments, antiulcer agents, and blood flow stimulants. The company also produces veterinary drugs such as vaccines, antibiotics, immune enhancers, enzymes, organic acid, and avian influenza-related agents, alongside animal feed supplements like pigments, kapok seed meal, and sesame meal. Functional food products, including enzymes and lactobacillus for dairy applications, form another revenue stream. The firm distributes these products domestically and internationally, targeting healthcare providers, veterinarians, and food manufacturers. The company's pharmaceutical segment serves medical professionals seeking treatments for cancer, infections, and gastrointestinal issues. Veterinary drug sales cater to animal health practitioners requiring vaccines and antibiotics for livestock. Animal feed supplements are sold to agricultural businesses, while functional food ingredients target dairy producers. CTC Bio, Inc. leverages its in-house pharmaceutical manufacturing technology and know-how to support product development and maintain competitive pricing. Revenue streams include direct sales of pharmaceuticals, veterinary drugs, animal feed supplements, and functional food ingredients. Domestic markets absorb the majority of these products, with international distribution expanding its reach. The company's focus on integrated production of pharmaceuticals, animal health solutions, and functional food components ensures consistent demand across multiple industry segments. CTC Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CTC Bio stock

Current Liabilities of CTC Bio is 5.28 B KRW in 2025.

Current Liabilities of CTC Bio changed from 59.72 B KRW to 5.28 B KRW, representing a -91.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities CTC Bio since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's CTC Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CTC Bio

All Key Metrics — CTC Bio